The bone-promoting actions of formononetin in established osteopenia

Menopause

Volumn 19, Issue 8, 2012, Pages 843-844

  Pru, James K ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; FORMONONETIN;

APOPTOSIS; ARTERIAL STIFFNESS; BLOOD PRESSURE; BONE METABOLISM; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFICACY; EDITORIAL; EPITHELIUM CELL; HUMAN; HYPERTROPHY; LEGUME; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; WOUND HEALING;

ANIMALS; BONE DISEASES, METABOLIC; FEMALE; ISOFLAVONES; OVARIECTOMY; PHYTOESTROGENS;

EID: 84864260688     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31825e9be3     Document Type: Editorial

References (24)

1. Gallagher JC, Levine JP. Preventing osteoporosis in symptomatic postmenopausal women. Menopause 2011;18:109-118.
2. Raisz LG, Prestwood KM. Epidemiology and pathogenesis of osteoporosis. Clin Cornerstone 2000;2:1-10.
3. Rungby J, Hermann A, Mosekilde L. Epidemiology of osteoporosis. Implications for drug therapy. Drugs Aging 1995;6:470-478.
4. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-271.
5. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormone status, lipids, genital tract and tolerability in postmenopausal women. Menopause 2005;12:202-209.
6. Briot K, Cortet B, Thomas T, et al. 2012 update on French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012;79:304-313.
7. Hopkins RB, Goerree R, Pullenayegum E, et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in postmenopausal women. BMC Musculoskelet Disord 2011;12:209.
8. Lee WL, Chao HT, Cheng MH, Wang PH. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 2008;60:92-107.
9. Barrett-Conner E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
10. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-1066.
11. Harris KB, Nealy KL, Jackson DJ, Thornton PL. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women. J Pharm Pract 2012;25:310-318.
12. Picherit C, Coxam V, Bennetau-Pelissero C, et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000;130:1675-1681.
13. Rachori D, Vortherms T, Seildova-Wuttke D, Wuttke W. Dietary daidzein and puerarin do not affect pituitary LH expression but exert uterotropic effects in ovariectomized rats. Maturitas 2007;57:161-170.
14. Rachon D, Vortherms T, Seidlova-Wuttke D, Menche A, Wuttke W. Uterotropic effects of dietary equol administration in ovariectomized Sprague- Dawley rats. Climacteric 2007;10:416-426.
15. Tyagi AM, Srivastava K, Singh AK, et al. Formononetin reverses established osteopenia in adult ovariectomized rats. Menopause 2012;19:856-863.
16. Mansoor TA, Ramalho RM, Luo X, Ramalhete C, Rodrigues CM, Ferreira MJ. Isoflavones as apoptosis inducers in human hepatoma HuH-7 cells. Phytother Res 2011;25:1819-1824.
17. Auyeung KK, Ko JK. Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cells. Invest New Drugs 2010;28:1-13.
18. Ye Y, Hou R, Chen J, et al. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation. Horm Metab Res 2012;44:263-267.
19. Huh JE, Nam DW, Baek YH, et al. Formononetin accelerates wound repair by the regulation of early growth response factor-1 transcription factor through the phosphorylation of the ERK and p38 MAPK pathway. Int Immunopharmacol 2011;11:46-54.
20. Wu JH, Li Q, Wu MY, et al. Formononetin, an isoflavone, relaxes rat isolated aorta through endothelium-dependent and endothelium-independent pathways. J Nutr Biochem 2010;21:613-620.
21. Zhao Y, Chen BN, Wang SB, Wang SH, Du GH. Vasorelaxant effects of formononetin in the rat thoracic aorta and its mechanisms. J Asian Nat Prod Res 2012;14:46-54.
22. Teede HJ, McGrath BP, DeSilva L, Cehun M, Fassoulakis A, Nestel PJ. Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausalwomen. Arterioscler Thromb Vasc Biol 2003;23:1066-1071.
23. Gautam AK, Bhargavan B, Tyagi AM, et al. Differential effects of formononetin and cladrin in osteoblast function, peak bone mass achievement and bioavailability in rats. J Nutr Biochem 2011;22:318-327.
24. Ha H, Lee HY, Lee JK, et al. Formononetin prevents ovariectomyinduced bone loss in rats. Arch Pharm Res 2010;33:625-632.